Market Overview:
The 7 major head and neck squamous cell carcinoma markets are expected to exhibit a CAGR of 8.2% during 2023-2033.
The head and neck squamous cell carcinoma market has been comprehensively analyzed in IMARC's new report titled "Head and Neck Squamous Cell Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033". Head and neck squamous cell carcinoma is a type of cancer that arises in the squamous cells lining the mucosal layers of the head and neck region. This disease typically begins in the oral cavity, throat, and voice box but can also occur in other areas, such as the nasal passages, sinuses, salivary glands, etc. The symptoms of the ailment can vary depending on the specific location of the tumor. Some of the common indications associated with this condition include a persistent sore throat, hoarseness or voice changes, difficulty swallowing or chewing, a lump or mass in the neck, mouth ulcers, ear pain, unexplained weight loss, etc. The diagnosis of head and neck squamous cell carcinoma typically involves a combination of medical history review, clinical feature assessment, and a physical examination. Various imaging techniques, such as positron emission tomography scans, X-rays, magnetic resonance imaging, etc., are used to identify the extent and location of the tumor. In some cases, the healthcare provider may further perform an endoscopy to visualize the throat, larynx, and other areas of the upper digestive tract.
.webp)
The increasing cases of excessive alcohol consumption and tobacco use, including smoking cigarettes, cigars, pipes, etc., which can cause DNA damage and lead to the formation of cancerous cells, are primarily driving the head and neck squamous cell carcinoma market. In addition to this, the rising prevalence of chronic irritation and inflammation of the oral cavity, often associated with poor hygiene practices, is also creating a positive outlook for the market. Moreover, the widespread adoption of targeted drugs, like cetuximab and pembrolizumab, which are designed to specifically aim at and inhibit certain molecules or pathways involved in cancer spread, is further bolstering the market growth. Apart from this, the escalating application of brachytherapy, since it involves placing radioactive sources directly into or near the tumor site to deliver a precise dose of radiation, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of combination treatment, such as chemoradiotherapy, owing to its several benefits, including enhanced effectiveness, reduced risk of local recurrence, improved survival rates, etc., is expected to drive the head and neck squamous cell carcinoma market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the head and neck squamous cell carcinoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for head and neck squamous cell carcinoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the head and neck squamous cell carcinoma market in any manner.
Time Period of the Study
- Base Year: 2022
- Historical Period: 2017-2022
- Market Forecast: 2023-2033
Countries Covered
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
Analysis Covered Across Each Country
- Historical, current, and future epidemiology scenario
- Historical, current, and future performance of the head and neck squamous cell carcinoma market
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across the head and neck squamous cell carcinoma market
- Reimbursement scenario in the market
- In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current head and neck squamous cell carcinoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Drugs |
Company Name |
Erbitux (Cetuximab) |
Eli Lilly and Company |
Taxotere (Docetaxel) |
Sanofi |
Keytruda (Pembrolizumab) |
Merck & Co |
Opdivo (Nivolumab) |
Bristol-Myers Squibb/Ono Pharmaceuticals |
Ladiratuzumab vedotin |
Merck/Seagen |
Lenvatinib |
Eisai Co Ltd/Merck & Co |
Xevinapant |
Debiopharm/Merck |
Magrolimab |
Gilead Sciences |
Tipifarnib |
Kura Oncology |
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
- How has the head and neck squamous cell carcinoma market performed so far and how will it perform in the coming years?
- What are the markets shares of various therapeutic segments in 2022 and how are they expected to perform till 2033?
- What was the country-wise size of the head and neck squamous cell carcinoma market across the seven major markets in 2022 and what will it look like in 2033?
- What is the growth rate of the head and neck squamous cell carcinoma market across the seven major markets and what will be the expected growth over the next ten years?
- What are the key unmet needs in the market?
Epidemiology Insights
- What is the number of prevalent cases (2017-2033) of head and neck squamous cell carcinoma across the seven major markets?
- What is the number of prevalent cases (2017-2033) of head and neck squamous cell carcinoma by age across the seven major markets?
- What is the number of prevalent cases (2017-2033) of head and neck squamous cell carcinoma by gender across the seven major markets?
- How many patients are diagnosed (2017-2033) with head and neck squamous cell carcinoma across the seven major markets?
- What is the size of the head and neck squamous cell carcinoma patient pool (2017-2022) across the seven major markets?
- What would be the forecasted patient pool (2023-2033) across the seven major markets?
- What are the key factors driving the epidemiological trend of head and neck squamous cell carcinoma?
- What will be the growth rate of patients across the seven major markets?
Head and Neck Squamous Cell Carcinoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
- What are the current marketed drugs and what are their market performance?
- What are the key pipeline drugs and how are they expected to perform in the coming years?
- How safe are the current marketed drugs and what are their efficacies?
- How safe are the late-stage pipeline drugs and what are their efficacies?
- What are the current treatment guidelines for head and neck squamous cell carcinoma drugs across the seven major markets?
- Who are the key companies in the market and what are their market shares?
- What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the head and neck squamous cell carcinoma market?
- What are the key regulatory events related to the head and neck squamous cell carcinoma market?
- What is the structure of clinical trial landscape by status related to the head and neck squamous cell carcinoma market?
- What is the structure of clinical trial landscape by phase related to the head and neck squamous cell carcinoma market?
- What is the structure of clinical trial landscape by route of administration related to the head and neck squamous cell carcinoma market?